Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET
Company Participants
Latha Vairavan – Vice President, Finance and Investor Relations
Frank Watanabe – President and CEO
Todd Edwards – Chief Commercial Officer
Patrick Burnett – Chief Medical Officer
David Topper – Chief Financial Officer
Conference Call Participants
Vikram Purohit – Morgan Stanley
Seamus Fernandez – Guggenheim Securities
Uy Ear – Mizuho
Serge Belanger – Needham & Co.
Kambiz Yazdi – Jefferies
Operator
Good day, and welcome to the Arcutis Biotherapeutics 2024 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation there will be a question-and-answer session. [Operator Instructions]. Please be advised that today’s conference is being recorded.
Now I’ll pass the call to Latha Vairavan, Vice President, Finance and Investor Relations. Please go ahead.
Latha Vairavan
Thank you, Carmen. Good afternoon, everyone, and thank you for joining us today to review our third quarter 2024 financial results and business update. Slides for today’s call are available on the Investor section of the Arcutis website. On the call today, we have Frank Watanabe, President and CEO; Patrick Burnett, Chief Medical Officer; Todd Edwards, Chief Commercial Officer; and David Topper, Chief Financial Officer.
I would like to remind everyone that we will be making forward-looking statements during this call. These statements are subject to certain risks and uncertainties, and our actual results may differ. We encourage you to review all the company’s filings with the Securities and Exchange Commission, including descriptions of our business and risk factor.
With that, let me hand the call over to Frank.
Frank Watanabe
Thank you, Latha, and thank you to everyone for joining us today. With that, let me turn to Slide 5 of the deck. I’m pleased to report that we maintained our
